Sulfinpyrazone after Myocardial Infarction: No Decision Yet

Publisher Website
Google Scholar
Abstract
In February 1978, the Journal published a preliminary report of the successful use of sulfinpyrazone (Anturane) in the prevention of sudden death after myocardial infarction.1 A second report, based on a longer period of treatment, appeared in January of this year2 and concluded that the drug reduced cardiac mortality by 32 per cent and sudden death by 43 per cent, as compared with a placebo. This seemingly dramatic and encouraging development was made all the more so by contrast with the disappointing results of a large-scale trial of aspirin that appeared at about the same time.3 Although sulfinpyrazone has antiplatelet . . .